4-(叔丁基氨基)苯甲酸 | 99985-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(叔丁基氨基)苯甲酸
• 英文名称: 4-tert-butylaminobenzoic acid
• 英文别名: 4-(Tert-butylamino)benzoic acid
• CAS: 99985-73-6
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: HSQUIQMFMBAAEB-UHFFFAOYSA-N

物化性质

• 熔点：
  152 °C
• 沸点：
  339.0±25.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  4-(叔丁基氨基)苯甲酸 、 4-((S)-2-Amino-4-methyl-pentanoylamino)-N-tert-butyl-benzamide; hydrochloride 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以43%的产率得到t-BuNHC6H4CO-Leu-NHC6H4CONH-t-Bu
  参考文献：
  名称：

  Right-Handed Helical Structure of Expanded Oligo(l-leucine) Containing [Ru(terpyridine)₂]²⁺ Moieties

  摘要：

  Expanded oligo(l-leucine)s, containing an alternate arrangement of a bis(terpyridine)ruthenium(II) moiety and a l-leucine residue, were synthesized and characterized by 1H NMR, UV, CD, and electrochemical properties. The intensity of CD spectra per ruthenium unit increased with the elongation of the peptide chain. 1H NMR analysis of a tetramer indicated the right-handed helical structure in acetonitrile.

  DOI：

  10.1021/ja044310j
• 作为产物：
  描述：

  苯佐卡因 在 氢氧化钾 、 硫酸 作用下， 以 乙醇 、 水 、 叔丁醇 为溶剂， 生成 4-(叔丁基氨基)苯甲酸
  参考文献：
  名称：

  Thiadiazoleamide derivative and anti-ulcer drug

  摘要：

  一种由以下化学式1表示的噻二唑酰胺衍生物或其盐：##STR1## 其中R.sub.1和R.sub.2中的每一个代表氢原子、较低的烷基基团、较低的烷氧基团、较低的烷基氨基团或烯氧基团；其中当R.sub.1或R.sub.2中的一个是氢原子时，另一个不是氢原子；R.sub.3代表较低的烷基基团、芳基、吡啶基或--N(R.sub.4)R.sub.5，其中R.sub.4和R.sub.5代表较低的烷基基团或一起代表具有4-8个成员的饱和杂环环；其中当R.sub.1或R.sub.2是较低的烷氧基团时，R.sub.3是--N(R.sub.4)R.sub.5或吡啶基；n代表1-3的整数。这些衍生物具有抗溃疡作用，可用于预防或治疗哺乳动物的溃疡。

  公开号：

  US05912258A1

文献信息

• [EN] NOVEL POTASSIUM CHANNEL BLOCKER<br/>[FR] NOUVEAU BLOQUANT DU CANAL POTASSIQUE
  申请人：XENTION LTD

  公开号：WO2010023445A1

  公开（公告）日：2010-03-04

  The present invention provides a compound of formula (I):or its salts or pharmaceutically acceptable derivatives wherein; R1 is selected from the group consisting of optionally substituted arylalkyl, optionally substituted aryl, optionally substituted heteroarylalkyl and optionally substituted heteroaryl; R2 is selected from the group consisting of optionally substituted acyl, optionally substituted sulfonyl and optionally substituted sulfamoyl; R3 is selected from the group consisting of hydrogen, halogen, hydroxyl, alkoxy, aryloxy, optionally substituted alkyl, optionally substituted amino, optionally substituted amino carbonyl, optionally substituted amino sulfonyl or nitrile; X1 is selected from a group consisting of a chemical bond, CR7R8, C(=O), C(=NH), NR9, NHC(O), and SO2 wherein; R7 and R8 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl and optionally substituted heteroaryl or; R7 and R8 together form an optionally substituted C4-6 cycloalkyl ring; R9 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl; A represents an optionally substituted saturated or partially saturated 4-7 membered ring with the general formula (A): or is selected from formula (B): For each occurrence; X2 is CH or N; X3 is CH2, CH(R5a), C(R5a)(R5b), NH, N(R5c), O or S; X4 is independently selected from C(=O), CH2, CH(R4a) or C(R4a)(R4b); R4a and R4b for each occurrence is independently halogen, optionally substituted amino, hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; R5a and R5b for each occurrence is independently, halogen, optionally substituted amino, hydroxyl, optionally substituted alkoxy, optionally substituted aryloxy, optionally substituted alkyl, optionally substituted alkanoyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; R5c is optionally substituted acyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; n = 1 or 2. The compounds are useful as potassium ion channel inhibitors.

  本发明提供了一种化合物，其化学式为(I)：或其盐或药学上可接受的衍生物，其中；R1选自可选择地取代的芳基烷基，可选择地取代的芳基，可选择地取代的杂芳基烷基和可选择地取代的杂芳基；R2选自可选择地取代的酰基，可选择地取代的磺酰基和可选择地取代的磺胺基；R3选自氢、卤素、羟基、烷氧基、芳氧基、可选择地取代的烷基、可选择地取代的氨基、可选择地取代的氨基羰基、可选择地取代的氨基磺酰基或腈的群；X1选自化学键、CR7R8、C(=O)、C(=NH)、NR9、NHC(O)和SO2的群，其中；R7和R8各自选自氢、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基和可选择地取代的杂芳基或；R7和R8一起形成一个可选择地取代的C4-6环烷基环；R9选自氢、可选择地取代的烷基、可选择地取代的芳基和可选择地取代的杂芳基；A代表一个可选择地取代的饱和或部分饱和的4-7成员环，其一般式为(A)：或选自式(B)：对于每次出现；X2为CH或N；X3为CH2、CH(R5a)、C(R5a)(R5b)、NH、N(R5c)、O或S；X4独立地选自C(=O)、CH2、CH(R4a)或C(R4a)(R4b)；R4a和R4b每次出现时独立地为卤素、可选择地取代的氨基、羟基、可选择地取代的烷氧基、可选择地取代的芳氧基、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；R5a和R5b每次出现时独立地为卤素、可选择地取代的氨基、羟基、可选择地取代的烷氧基、可选择地取代的芳氧基、可选择地取代的烷基、可选择地取代的烷酰基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；R5c为可选择地取代的酰基、可选择地取代的烷基、可选择地取代的环烷基、可选择地取代的芳基烷基、可选择地取代的芳基或可选择地取代的杂芳基；n = 1或2。这些化合物可用作钾离子通道抑制剂。
• CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
  申请人：Sufi Bilal

  公开号：US20100145036A1

  公开（公告）日：2010-06-10

  The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物和药物可切割底物共轭物，它们是有效的细胞毒素。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20080125399A1

  公开（公告）日：2008-05-29

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR）。这些化合物有助于增强肌肉张力减弱和治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病，包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、老化皮肤、男性性腺功能减退、女性绝经后症状、动脉硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、良性前列腺增生症（BPH）、癌症消耗综合征、阿尔茨海默病、肌营养不良、认知能力下降、性功能障碍、睡眠呼吸暂停、抑郁症、早发性卵巢衰竭和自身免疫性疾病，可单独使用或与其他活性剂联合使用。
• Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
  申请人：Clairmont Kevin

  公开号：US20090280106A1

  公开（公告）日：2009-11-12

  This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

  本发明提供了具有新颖修饰的肽，这些修饰提供了适合衍生化的位点，以改善肽的药代动力学特性。这些修饰后的肽在体内作为VPAC2受体的激动剂发挥作用。本发明的肽为具有内源性胰岛素分泌减少的患者，例如2型糖尿病患者提供了新的治疗方法。
• CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF
  申请人：Chen Liang

  公开号：US20100113476A1

  公开（公告）日：2010-05-06

  The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体结合物，其具有强效的细胞毒性，并在药物和配体之间包含一个仅有一个氨基酸的连接物。本公开还涉及包含药物-配体结合物的组合物以及使用它们的治疗方法。